Logo
x

Search category

Subscribe Now

ViiV Healthcare

ViiV Healthcare’s Apretude (cabotegravir long-acting injectable and tablets) Receives EC’s Approval for HIV Prevention

ViiV Healthcare’s Apretude (cabotegravir long-acting injectable and tablets) Receives EC’s Approval for HIV Prevention

  • September 19, 2023
ViiV Healthcare Receives EMA’s CHMP Positive Opinion of Cabotegravir for HIV Prevention

ViiV Healthcare Receives EMA’s CHMP Positive Opinion of Cabotegravir for HIV Prevention

  • July 24, 2023
Dr. Harmony Garges, CMO at ViiV Healthcare, Shares Insights on Positive Findings from the SOLAR Study of Cabenuva

Dr. Harmony Garges, CMO at ViiV Healthcare, Shares Insights on Positive Findings from the SOLAR Study of Cabenuva

  • May 19, 2023
ViiV Healthcare Receives EC's Marketing Authorisation of Triumeq PD for the Treatment of Human Immunodeficiency Virus Type 1

ViiV Healthcare Receives EC's Marketing Authorisation of Triumeq PD for the Treatment of Human Immunodeficiency Virus Type 1

  • February 22, 2023
ViiV Healthcare Presents Five-Year P-III (BRIGHTE) Study Results of Fostemsavir for Multidrug-Resistant HIV-1 Infection at AIDS 2022

ViiV Healthcare Presents Five-Year P-III (BRIGHTE) Study Results of Fostemsavir for Multidrug-Resistant HIV-1 Infection at AIDS 20...

  • August 1, 2022
PharmaShots Interview: In Conversation with ViiV Healthcare's Sr. VP, Kimberly Smith, Where she Shares Insights on the US FDA Approval for Label Update of its Lead Candidate in HIV

PharmaShots Interview: In Conversation with ViiV Healthcare's Sr. VP, Kimberly Smith, Where she Shares Insights on the US FDA Appr...

  • June 29, 2022
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2023 PharmaShots - All Rights Reserved.